穴位贴敷减轻肿瘤合并肺结核患者消化道不良反应的疗效

doi:10.3760/cma.j.cn441417-20250324-12018

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (12): 2017-2021.DOI: 10.3760/cma.j.cn441417-20250324-12018

穴位贴敷减轻肿瘤合并肺结核患者消化道不良反应的疗效

曾云云¹ 蔡京伦² 黄智昊¹ 黄惠怡¹ 刘嘉淇¹ 苏珊¹

¹广州市胸科医院肿瘤科，广州 510095；²广州华夏职业学院卫生健康学院，广州 510935

收稿日期:2025-03-24 出版日期:2025-06-15 发布日期:2025-06-15
通讯作者: 苏珊，Email：susan705@126.com
基金资助:
国家自然科学基金（82003304）；广东省自然科学基金（2022A1515012400）；广州市科技市校（院）企联合资助项目（2024A03J0581）；CTONG-默沙东肺癌科研基金（CTONG-YC20210203）

Efficacy of acupoint application in relieving gastrointestinal adverse reactions in patients with tumors and pulmonary tuberculosis

Zeng Yunyun¹, Cai Jinglun², Huang Zhihao¹, Huang Huiyi¹, Liu Jiaqi¹, Su Shan¹

¹Oncology Department, Guangzhou Chest Hospital, Guangzhou 510095, China; ²School of Health, Guangzhou Huaxia Vocational College, Guangzhou 510935, China

Received:2025-03-24 Online:2025-06-15 Published:2025-06-15
Contact: Su Shan, Email: susan705@126.com
Supported by:
National Natural Science Foundation (82003304); Guangdong Natural Science Foundation (2022A1515012400); Municipal-University-Enterprise Joint Funding Project of Science and Technology in Guangzhou (2024A03J0581); CTONG- Merck Lung Cancer Research Fund (CTONG-YC20210203)

摘要/Abstract

摘要：

目的　探讨中药穴位贴敷对肿瘤合并肺结核患者化疗联合抗结核治疗相关消化道不良反应的临床疗效。方法　选取2022年1月至2024年10月在广州市胸科医院肿瘤科进行化疗联合抗结核治疗的中晚期肿瘤合并活动性肺结核的患者44例为研究对象。根据临床止吐治疗方案，将其分为常规止吐治疗组和穴位贴敷治疗组，各22例。常规止吐治疗组男21例，女1例，年龄（62.957±8.014）岁，肺癌患者14例，消化道肿瘤患者8例；穴位贴敷治疗组男20例，女2例，年龄（63.900±8.296）岁，肺癌患者12例，消化道肿瘤患者7例，其他类型肿瘤患者3例。穴位贴敷治疗组在常规止吐治疗方案基础上联合中药穴位贴敷治疗。对比两组患者消化道不良反应、肝功能损伤、骨髓抑制、化疗后营养指标、化疗后CD4和CD8细胞计数、住院时间等。采用t检验和χ2检验进行统计分析。结果　常规止吐治疗组消化道不良反应发生率高于穴位贴敷治疗组（P<0.05）。穴位贴敷治疗组转氨酶升高发生率、化疗后白蛋白水平［（38.012±4.304）g/L比（33.782±4.415）g/L］、上臂围［（34.700±2.203）cm比（30.200±1.936）cm］优于常规止吐治疗组（均P<0.05）。常规止吐治疗组住院时间（10.620±0.160）d，穴位贴敷治疗组（9.788±0.331）d，差异有统计学意义（P<0.05）。结论　中药穴位贴敷联合常规止吐治疗方案可以减轻肿瘤合并肺结核患者在化疗联合抗结核治疗中的消化道不良反应发生率，减少肝功能损伤的发生，降低化疗及抗结核治疗引起的蛋白质-热能营养不良发生率，减少中重度化疗后骨髓抑制的发生，减少住院时间，提高患者生活质量。

关键词: 化疗, 抗结核治疗, 肿瘤合并肺结核, 中药穴位贴敷, 止吐治疗

Abstract:

Objective　To explore the clinical efficacy of traditional Chinese medicine (TCM) acupoint application in treating related gastrointestinal adverse reactions caused by chemotherapy and anti-tuberculosis treatment in patients with tumors and pulmonary tuberculosis. Methods　From January 2022 to October 2024, 44 patients with advanced-stage tumors and active pulmonary tuberculosis undergoing chemotherapy and anti-tuberculosis treatment in Oncology Department, Guangzhou Chest Hospital were selected as the study objects. According to the clinical antiemetic treatment plans, they were divided into a conventional antiemetic treatment group (22 cases) and an acupoint application treatment group (22 cases). In the conventional antiemetic treatment group, there were 21 males and 1 female; they were (62.957±8.014) years old; there were 14 cases of lung cancer and 8 cases of digestive tract tumors. In the acupoint application treatment group, there were 20 males and 2 females; they were (63.900±8.296) years old; there were 12 cases of lung cancer, 7 cases of digestive tract tumors, and 3 of other types of tumors.The acupoint application treatment group took TCM acupoint application therapy and conventional antiemetic treatment. The gastrointestinal adverse reactions, liver function damage, bone marrow suppression, nutritional indicators after chemotherapy, CD4 and CD8 cell counts after chemotherapy, and hospitalization times were compared between the two groups by t and χ² tests. Results　The incidence rate of gastrointestinal adverse reactions in the conventional antiemetic treatment group was higher than that in the acupoint application treatment group (P<0.05). The incidence rate of transaminase elevation, albumin level after chemotherapy [(38.012±4.304) g/L vs. (33.782±4.415) g/L], and upper arm circumference [(34.700±2.203) cm vs. (30.200±1.936) cm] in the acupoint application treatment group were better than those in the conventional antiemetic treatment group (all P<0.05). The hospitalization time in the conventional antiemetic treatment group was longer than that in the acupoint application treatment group [(10.620±0.160) d vs. (9.788±0.331) d], with a statistical difference (P<0.05). Conclusion　The combination of TCM acupoint application with conventional antiemetic treatment for patients with advanced-stage tumors and pulmonary tuberculosis undergoing chemotherapy and anti-tuberculosis treatment can reduce the incidence of gastrointestinal adverse reactions, liver function damage, protein-energy malnutrition caused by chemotherapy and anti-tuberculosis treatment for tumors and tuberculosis, and moderate to severe bone marrow and suppression after chemotherapy, shorten the hospitalization time, and improve their quality of life.

Key words: Chemotherapy, , Anti-tuberculosis treatment, , Tumor and pulmonary tuberculosis, , TCM acupoint application, , Antiemetic treatment

曾云云蔡京伦黄智昊黄惠怡刘嘉淇苏珊. 穴位贴敷减轻肿瘤合并肺结核患者消化道不良反应的疗效 [J]. 国际医药卫生导报, 2025, 31(12): 2017-2021.

Zeng Yunyun, Cai Jinglun, Huang Zhihao, Huang Huiyi, Liu Jiaqi, Su Shan.

Efficacy of acupoint application in relieving gastrointestinal adverse reactions in patients with tumors and pulmonary tuberculosis [J]. International Medicine and Health Guidance News, 2025, 31(12): 2017-2021.

参考文献

[1]Ye MF, Su S, Huang ZH, et al. Efficacy and safety of concurrent anti-tuberculosis treatment and chemotherapy in lung cancer patients with co-existent tuberculosis [J]. Ann Transl Med, 2020, 8(18):1143. DOI: 10.21037/atm-20-5964.

[2]王霞,张萃,崔佳,等.穴位贴敷联合常规止吐药预防化疗患者不良反应疗效观察[J].现代中西医结合杂志,2020,29(33):3738-3741. DOI:10.3969/j.issn.1008-8849. 2020.33.023.

[3]王宝仪,张锂泰,高宇,等.穴位贴敷防治化疗恶心呕吐的研究进展[J].现代中西医结合杂志,2020,29(24):2726-2730. DOI:10.3969/j.issn.1008-8849.2020.24.025.

[4]王泽文,王振强.化疗相关性恶心呕吐的中西医研究进展[J].中外医学研究,2024,22(18):176-179. DOI:10.14033/j.cnki.cfmr.2024.18.041.

[5]吴洁如,施伎蝉,徐瑶琪,等.中药穴位贴敷对抗结核药物所致恶心呕吐反应的影响[J].新中医, 2023,55(15):171-174.

[6]WHO consolidated guidelines on tuberculosis: Module 1: Prevention - Infection prevention and control[M]. Geneva: World Health Organization, 2022.

[7]林丽珠,王思愚,黄学武.肺癌中西医结合诊疗专家共识[J].中医肿瘤学杂志,2021,3(6):1-17. DOI:10.19811/j.cnki.ISSN2096-6628.2021.06.001.

[8]孟学兵,陈爱军.老年肺结核患者抗结核药物的不良反应研究[J].中国防痨杂志,2024,46(z1):76-78. DOI:10.3969/j.issn.1000-6621.2024.z1.020.

[9]孟学兵,陈爱军.老年肺结核患者抗结核药物的不良反应研究[J].中国防痨杂志,2024,46(z1):76-78. DOI:10.3969/j.issn.1000-6621.2024.z1.020.

[10]龚菊芳,钟小艳,晏雪花,等.穴位贴敷联合盐酸帕洛诺司琼治疗恶性肿瘤患者化疗后呕吐的疗效分析[J].现代诊断与治疗,2022,33(8):1118-1120.

[11]周松晶,史佳,韩平.中药穴位贴敷联合托烷司琼治疗肿瘤化疗致临床症状的随机对照研究[J].湖北中医药大学学报,2021,23(2):82-85. DOI:10.3969/j.issn.1008- 987x. 2021.02.23.

[12]周健,杨俊,钟燕霞.中医穴位贴敷结合标准止吐方案对恶性肿瘤患者化疗所致恶心呕吐的防治效果观察[J].反射疗法与康复医学,2024,5(3):8-10,15.

[13]施海瑜,夏卫明.降逆止呕方穴位贴敷治疗肺癌患者化疗后恶心呕吐的效果分析[J].大医生,2024,9(7):102-104. DOI:10.3969/j.issn.2096-2665.2024.07.034.

[14]邹汉飞.四黄散腹部穴位贴敷治疗恶性肿瘤化疗后消化道反应的临床疗效研究[J].中医临床研究, 2020,12(32):10-13.

[15]彭树灵,张卫华,钟育波,等.健脾益气方联合穴位贴敷防治大肠癌术后化疗性胃肠反应的有效性研究[J].国际医药卫生导报,2022,28(11):1516-1520. DOI:10.3760/cma.j.issn.1007-1245.2022.11.009.

[16]王霞,张萃,崔佳,等.穴位贴敷联合常规止吐药预防化疗患者不良反应疗效观察[J].现代中西医结合杂志,2020,29(33):3738-3741. DOI:10.3969/j.issn.1008-8849. 2020.33.023.

[17]李利菊,朱丽,徐有祖.穴位贴敷对肺癌化疗相关性腹泻患者肠黏膜屏障的作用[J].中国现代医生, 2020,58(35):144-147.

[18]葛婷,潘龙赐,刘志勇.穴位敷贴结合托烷司琼治疗化疗所致恶心呕吐的临床疗效[J].现代肿瘤医学,2022,30(10):1870-1874. DOI:10.3969/j.issn.1672-4992.2022.10.031.

[19]薛晴,丛竹凤,向泽栋,等.近十年中药穴位贴敷制剂研究评述[J].中国中医基础医学杂志,2022,28(5):785-791.

[20]杨红杰,齐菲,张红梅,等.肺癌合并肺结核的诊断和临床治疗现状[J].结核与肺部疾病杂志,2024,5(3):273-278. DOI:10.19983/j.issn.2096-8493.2024054.

[21]林琪,夏传宝,陈阳天,等.穴位贴敷联合艾灸对肺癌化疗患者骨髓抑制的防治作用[J].中外医疗,2022,41(33):171-175. DOI:10.16662/j.cnki.1674-0742.2022.33.171.

[22]马仲序,童晓燕,唐理斌,等.中药穴位贴敷联合常规抗结核治疗对复治肺结核患者疗效分析[J].中外医疗,2021,40(12):149-151. DOI:10.16662/j.cnki.1674-0742. 2021.12.149.

穴位贴敷减轻肿瘤合并肺结核患者消化道不良反应的疗效

Efficacy of acupoint application in relieving gastrointestinal adverse reactions in patients with tumors and pulmonary tuberculosis

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	赵爱梅王晓莉王梅曹宁宁张芳朱亚农. 中药穴位贴敷按摩对气滞血瘀型初产妇分娩质量的影响 [J]. 国际医药卫生导报, 2025, 31(6): 1011-1015.
[2]	曹东东聂娟利. 标准化疗方案联合百合地黄汤治疗老年肺结核患者的疗效 [J]. 国际医药卫生导报, 2025, 31(5): 839-843.
[3]	杜露露朱趁红刘瑞莹孙静. 赋能理论指导的自我管理模式在急性髓系白血病化疗患者中的应用 [J]. 国际医药卫生导报, 2025, 31(5): 870-874.
[4]	张愉张恺铄曹洪友高山. 尼妥珠单抗靶向治疗局部晚期鼻咽癌患者的临床疗效观察 [J]. 国际医药卫生导报, 2025, 31(4): 669-673.
[5]	王效邓智平张习凡李阳张彧. 多学科协作对乳腺癌化疗致周围神经病变患者的作用 [J]. 国际医药卫生导报, 2025, 31(12): 2093-2097.
[6]	郭婉贞刘向阳朱建欣. “互联网+”模式护理干预对食管癌化疗患者心理弹性水平的影响 [J]. 国际医药卫生导报, 2025, 31(12): 2098-2103.
[7]	沈勇郑春梅. GGT水平预测TACE联合索拉菲尼治疗原发性肝癌患者效果的价值 [J]. 国际医药卫生导报, 2025, 31(10): 1675-1680.
[8]	邱换换葛高琪郭瑾刘建芳路亚婉. 基于主观整体营养评估量表评分的营养干预对结直肠癌患者化疗期营养摄入和生活质量的影响 [J]. 国际医药卫生导报, 2025, 31(1): 136-140.
[9]	张国坤张天佑张景畅李素新. 原发性肝癌患者TACE预后不良的因素分析：基于PSM法 [J]. 国际医药卫生导报, 2024, 30(5): 747-753.
[10]	路晓雯刘梓洋. 增强CT联合超声造影在HCC患者TACE疗效评估中的应用 [J]. 国际医药卫生导报, 2024, 30(5): 754-758.
[11]	高永昌姚庆娟. 难治性局部晚期三阴性乳腺癌患者新辅助化疗后肿瘤异质性1例 [J]. 国际医药卫生导报, 2024, 30(4): 632-634.
[12]	黄敏清庄文行王影邱丽欢王方. 肿瘤科护士化疗相关性恶心呕吐知信行现状的调查研究 [J]. 国际医药卫生导报, 2024, 30(4): 657-661.
[13]	于潇杰程立浩张浩张浩杰杨振林. 铁死亡与乳腺癌患者化疗耐药的关系研究进展 [J]. 国际医药卫生导报, 2024, 30(3): 353-356.
[14]	徐军陈君平王健吕东来. Napsin A表达与二线及以上贝伐珠单抗联合化疗方案治疗晚期肺腺癌疗效的相关性 [J]. 国际医药卫生导报, 2024, 30(24): 4125-4131.
[15]	王淑红常英张莉霞. 伏美替尼联合GC化疗方案对非小细胞肺癌患者的疗效观察 [J]. 国际医药卫生导报, 2024, 30(24): 4141-4145.